In direct compression of liposomal vitamin K2 pharma grade API onto a 45-station rotary press with external lubrication, dry powder handling is constrained by the phospholipid content of the carrier and the low mechanical strength of the liposomal membrane. The API is screened through a 500 μm stainless-steel sieve and premixed with microcrystalline cellulose PH102 and partially pregelatinized starch at a 70:30 ratio. The active fraction is incorporated at 2.0–10.0 wt% lipid-adjusted basis; croscarmellose sodium 2.0 wt% is added as disintegrant, and sodium stearyl fumarate 1.5 wt% is introduced in a final low-shear V-blender at 12 rpm for 3 min. The blend is transferred under dry nitrogen into the press hopper, and tablets are compressed on 10 mm round convex tooling to a target breaking force of 60–100 N as measured by USP <1217>. Compression force is held between 7.5 kN and 12 kN with precompression not exceeding 5 kN and turret speed between 30 rpm and 60 rpm. Published data for this specific API is limited, but for liposomal powders with similar hydrogenated phosphatidylcholine content, compression forces above 16 kN have produced edge exudation of lipid and capping on production-scale rotary presses, while forces below 6 kN produce insufficient hardness and friability above 1.0% by USP <1216>. Tablet weight variation is monitored per USP <905> and dissolution is assessed in 900 mL of 0.1 M hydrochloric acid at 37 ± 0.5 °C with paddle speed 50 rpm under USP <711>. If a film coat is required, a non-aqueous hydroxypropyl cellulose-based coating is applied at 2–3 wt% solids in a perforated pan with inlet air 40–50 °C; aqueous coating is avoided because residual water plasticises the phospholipid layer and causes surface tacking. Finished tablets are stored in HDPE containers with desiccant at 25 °C / 60% RH and are protected from light because menaquinone-7 can undergo light-induced isomerisation. Release testing follows FDA 21 CFR 211.165.

Why Does Dosator Filling Fail When Lipid Load Exceeds 25% in HPMC Capsules?

The failure mode is powder bed consolidation under the dosator pin and lipid bridging at the nozzle. On a dosator-type encapsulator, the powder slug is formed inside the dosator body at a compression force determined by spring pressure and fill depth. With liposomal K2 loadings above 25 wt%, the phospholipid fraction softens under frictional heat generated during compaction, producing stick-slip ejection and incomplete transfer into HPMC capsule shells. This is observed at fill depths above 12 mm on a size 0 HPMC capsule with a target fill weight of 300 mg. Tamping-pin fillers operating with 1–3 tamping stations and low tamping force are preferred because the powder bed experiences lower compressive stress. The dry blend is prepared with lactose monohydrate 80M, microcrystalline cellulose PH102 at 20 wt%, fumed silica at 0.5–1.0 wt%, and sodium stearyl fumarate 0.5 wt%. Blend flow is characterised by USP <1174>; a Carr index below 25% and Hausner ratio below 1.25 are required before filling. The HPMC shells are conditioned at 40–50% RH for at least 24 h, because shell moisture below 35% RH causes brittle fracture on closing, and above 60% RH causes softening and deformation. After filling, capsules are assessed for weight variation by USP <905>, dissolution by USP <711>, and capsule integrity is checked by visual inspection and, where specified, blister leak testing according to USP <671> container–closure permeability. For oxygen-sensitive liposomal K2, the blister cavity is formed from cold form foil or PVC/PVDC with aluminium lidding; oxygen permeation is limited to ≤0.01 cm³/m²/day/atm at 23 °C and 0% RH. Published data for this specific API is limited; the 25 wt% threshold is derived from liposomal powder behaviour on production-scale equipment and should be re-established for each phospholipid composition and capsule size.

When oral granules are required for reconstitution into a suspension or for direct sprinkle use, dry compression and capsule filling are replaced by low-temperature fluid-bed granulation because the liposomal phospholipid bilayer can undergo phase transitions if exposed to high-shear wet massing. A top-spray fluid-bed granulator with a Glatt GPCG 5.1 bowl is charged with liposomal vitamin K2 API, maltodextrin DE10, and trehalose dihydrate. The binder is a 10% w/w trehalose solution containing 5% w/w maltodextrin, sprayed at a rate of 25–35 g/min; inlet air temperature is set to 50–55 °C, product temperature is maintained at 32–38 °C, and the dew point is controlled to 8–10 °C. These conditions avoid the main gel-to-liquid crystalline phase transition of hydrated phosphatidylcholine bilayers, which for many liposomal systems occurs between 40 °C and 55 °C, although published data for this specific vitamin K2 liposomal API is limited. Granulation is continued until the D50 by sieve analysis reaches 150–250 μm. The granulate is dried in the same fluid bed to a moisture content of ≤2.0% by Karl Fischer titration, then screened through an 800 μm stainless-steel screen. Silicon dioxide 0.3 wt% is added to reduce static and to prevent bridging in sachet filling. Granules are filled into aluminium foil/PE laminate sachets under nitrogen with residual oxygen below 1.0%; seal strength is verified on a tensile tester according to ASTM F88/F88M-21, with a minimum seal force of 12 N/15 mm. Content uniformity is tested by Ph. Eur. 2.9.40, and moisture content is rechecked after sealing. For a finished granule intended for reconstitution, the suspension pH is adjusted to 6.0–7.0 after reconstitution with purified water. The main failure mode on production-scale fluid-bed wet granulation is nozzle dripping leading to localised overwetting and liposomal membrane disruption; this is controlled by monitoring atomisation air pressure at 1.8–2.5 bar and by periodic nozzle purge with nitrogen.

Terminal Sterilisation Is Replaced by Aseptic Filtration in Injectable Liposomal Vitamin K2

Preparation of an injectable liposomal vitamin K2 dispersion requires control of particle size below sterile filtration thresholds, maintenance of sterility assurance, and avoidance of phospholipid hydrolysis during processing. A preformed liposomal dispersion is processed through a piston-gap high-pressure homogeniser at 800–1000 bar for 5–8 discrete passes. The product stream is passed through a stainless-steel shell-and-tube heat exchanger to keep the outlet temperature at 10–15 °C; higher wall shear in the interaction chamber can generate local temperature excursions that hydrolyse hydrogenated soybean phosphatidylcholine and raise free fatty acid content. The batch is buffered with 10 mM phosphate buffer at pH 6.5–7.0, and tonicity is adjusted with sodium chloride 0.9% w/v or glycerol 2.25% w/v. For a long-circulating formulation, DSPE-PEG2000 is incorporated at 4–6 mol% of total phospholipid; this steric component shifts the zeta potential measured by electrophoretic light scattering to between −15 mV and −30 mV. Particle size is measured by dynamic light scattering after each pass; a D90 below 200 nm is required for sterilising-grade filtration through a 0.22 μm polyethersulfone membrane. If D90 exceeds 200 nm, filtration is replaced by aseptic assembly of presterilised components under ISO 14644-1 Class 5 conditions. Terminal steam sterilisation at 121 °C for 15 min is generally avoided because it destabilises the liposomal bilayer and increases particle size beyond the sterile filtration limit. The filled vials are tested for sterility by USP <71>, bacterial endotoxin by USP <85>, particulate matter by USP <788> light obscuration method, and visible particles by USP <790>. Osmolality is controlled to 280–320 mOsm/kg by USP <785>. Residual hydrogenated phospholipid oxidation products are monitored during stability according to ICH Q1A(R2), and elemental impurities are assessed under ICH Q3D. The key production failure observed on pilot-scale filling lines is shear-induced foam generation during circulation, which can lead to bubble entrapment in vials and underdosing; degassing under vacuum at −0.7 to −0.9 bar for 10 min and slow peristaltic transfer at 40–60 rpm reduce foam. Published data for the terminal sterilisation stability of this specific liposomal vitamin K2 API is limited.

When Multidose Oral Liquids Require Preservative Efficacy Without Liposome Leakage

Multidose oral liquid dosage forms containing liposomal vitamin K2 must simultaneously pass antimicrobial effectiveness testing and preserve the particle size distribution of the liposomal dispersion. A preservative system based on sodium benzoate 0.1% w/v and potassium sorbate 0.05% w/v is selected because parabens are avoided in some paediatric and oncology-adjacent protocols and because benzalkonium chloride can disrupt negatively charged liposomes. The liquid vehicle contains purified water, glycerol 2.25% w/v, disodium edetate 0.005% w/v, and α-tocopherol 0.01% w/v as antioxidant; the pH is adjusted to 6.0–6.8 with 10 mM citrate or phosphate buffer. The liposomal API is added as a concentrated dispersion and diluted to a final vitamin K2 concentration of 100 μg/mL with low-shear mixing at 300–500 rpm for 20 min. High-shear homogenisation at 12,000 rpm for 10 min may be used only if the D90 target of ≤250 nm is not met after dilution; prolonged high shear can cause phospholipid oxidation and leakage of menaquinone-7 from the bilayer. Particle size is monitored by dynamic light scattering, with polydispersity index below 0.25, and zeta potential is measured by electrophoretic light scattering, with an acceptance range of −15 mV to −35 mV. The finished liquid is filled into amber borosilicate glass bottles with child-resistant closures; a fill volume tolerance of ±2% is applied. Antimicrobial effectiveness is evaluated by USP <51> using prescribed organisms; any log reduction failure requires reformulation of the preservative system rather than an increase in lipid content, because higher lipid content increases the substrate load on the membrane and accelerates vesicle coalescence. Storage at 2–8 °C is typical because the lipid bilayer is sensitive to repeated freeze–thaw cycles; freezing produces ice-crystal rupture and drug leakage. Published data for this specific liposomal API is limited, but the preservative incompatibility mechanisms are known for suspension-grade liposomal dispersions.

Lyophilised Orodispersible Granule in Blister with Low-Permeation Lidding

Lyophilisation of liposomal vitamin K2 into an orodispersible granule format requires a cryoprotectant matrix with a high glass transition temperature and a low residual moisture specification. The process starts with a dispersion containing liposomal vitamin K2, trehalose 4.0% w/v, mannitol 2.0% w/v, and phosphate buffer 5 mM at pH 6.5. This dispersion is filled into preformed blister cavities at a target dose volume of 0.5 mL per cavity, then lyophilised in a production-scale freeze dryer with shelf settings of −40 °C for freezing, primary drying at −20 °C and 0.1–0.2 mbar for 24–36 h, and secondary drying at +25 °C for 6 h. The residual moisture of the lyophilised product is ≤1.5% by Karl Fischer titration. Mannitol is used only at low concentration because its crystallisation during annealing can disrupt liposomal bilayers; when required for physical strength, controlled freezing at 0.5 °C/min ramp is applied to reduce crystal damage. The lyophilised units are sealed with lidding foil that provides an oxygen permeation limit of ≤0.01 cm³/m²/day/atm and a moisture vapour transmission rate below 0.1 g/m²/day at 38 °C / 90% RH. Seal strength is tested according to ASTM F88/F88M-21 with a minimum value of 10 N/15 mm. The orodispersible unit is evaluated by USP <701> for disintegration, with a target of ≤30 s in 37 ± 0.5 °C purified water. The main production-scale defect in this format is collapse of the lyophilised matrix when the glass transition temperature of the trehalose-mannitol phase is exceeded during primary drying; this is controlled by maintaining the shelf temperature below the collapse temperature and by limiting chamber pressure rise due to sublimation overload. Because the liposomal membrane can aggregate during freezing, the ratio of trehalose to mannitol is adjusted so that amorphous trehalose remains the dominant cryoprotectant. Published data for this specific API in lyophilised orodispersible form is limited.